Citigroup Maintains Buy on Evolent Health, Raises Price Target to $5.5

Benzinga Newsdesk www.benzinga.com Positive 73.4%

Neg 0% Neu 0% Pos 73.4%

Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.5.